GRI Bio reported Q2 2024 financial results and provided updates on its lead program GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The company remains on track for interim data readout in Q4 2024 and topline results in Q1 2025 from its Phase 2a biomarker study.The company recorded a net loss of $2.4 million for Q2 2024, with research and development expenses of $0.9 million and general and administrative expenses of $1.4 million. In June 2024, GRI Bio completed a public offering raising $4.0 million in gross proceeds. As of June 30, 2024, the company had cash and cash equivalents of $6.4 million.GRI Bio continues to advance its secondary program GRI-0803 for systemic lupus erythematosus treatment, generating encouraging preclinical data. The company expects its current cash position to fund operations into Q1 2025 and plans to raise additional capital to support ongoing operations.

GRI Bio reported Q2 2024 financial results and provided updates on its lead program GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The company remains on track for interim data readout in Q4 2024 and topline results in Q1 2025 from its Phase 2a biomarker study.The company recorded a net loss of $2.4 million for Q2 2024, with research and development expenses of $0.9 million and general and administrative expenses of $1.4 million. In June 2024, GRI Bio completed a public offering raising $4.0 million in gross proceeds. As of June 30, 2024, the company had cash and cash equivalents of $6.4 million.GRI Bio continues to advance its secondary program GRI-0803 for systemic lupus erythematosus treatment, generating encouraging preclinical data. The company expects its current cash position to fund operations into Q1 2025 and plans to raise additional capital to support ongoing operations.